We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bulldog Bio Provides Novel Adjuvant Enhancer for Improved Vaccinations

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bulldog Bio Provides Novel Adjuvant Enhancer for Improved Vaccinations"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioCellChallenge's newly developed Opticcine Adjuvant Enhancer improves an immune response against a wide variety of antigens without negative effects. Based upon the well understood mannose activation of the immune system, this highly pure version of Man-DOG (Monomannosyl-dioleyl glycerol) works at incredibly low concentrations.

Bulldog Bio has been granted the exclusive right to promote, sell and support this product to researchers and companies throughout North America.

"Current customers throughout Europe have already seen marked improvement in vaccine design using this unique form of Man-DOG. In fact, our first customer has already had a vaccine enter phase 3 clinical trials." stated Laurent Meunier, CEO of BioCellChallenge.

BioCellChallenge SAS is a privately held biotechnology company, founded in 2009. The company specializes in drug delivery systems and aims to provide exceptional tools to the scientific community.